Clinical Biomarkers Market New Growth Opportunities

A quick peek into the report

Market Overview

Global clinical biomarkers market analysis by BIS Research projects the market to grow at a significant CAGR of 10.07% during the

Key Questions Answered in this Report:

What are the major market drivers, challenges, and opportunities in the global clinical biomarkers market?

Report Description

Global clinical biomarkers market research provides a holistic view of the market in terms of various factors influencing it, incl

Scope of the Market Intelligence on Global Clinical Biomarkers Market

Global clinical biomarkers market research provides a holistic view of the market in terms of various factors influencing it, including strategic developments and technological advancements.

The scope of this report is centered upon conducting a detailed study of the products and manufacturers allied with the industrial and biological research. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, growth potential of each underlying sub-segment, and company, as well as other vital information with respect to global clinical biomarkers market.

Market Segmentation

Global clinical biomarkers market (on the basis of type) is segmented into diagnostic, prognostic and predictive biomarkers.

Global clinical biomarkers market (on the basis of clinical area) is segmented into cancer biomarkers, cardiac biomarkers, neurological biomarkers, infectious disease, immunological biomarkers, non-invasive prenatal testing and other clinical areas.

Global clinical biomarkers market (on the basis of technology) is segmented into real-time polymerase chain reaction, next-generation sequencing, Enzyme-linked immunosorbent assay (ELISA), and other technologies.

Global clinical biomarkers market (on the basis of end user) is segmented into research and academic laboratories, diagnostic centers, biopharmaceutical and biotech companies and other end users.

Key companies in the Global Clinical Biomarkers Market

The report also comprises 15 detailed company profiles including several key players, such as Abbott Laboratories, Agilent Technologies, Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, Myriad Genetics, Hologic, Inc., Bio-Rad Laboratories, Inc., Qiagen N.V., Enzo Biochem Inc., Centogene N.V., ALCEDIAG, and Quest Diagnostics Incorporated.

1.1 Inclusion and Exclusion

2.1 Scope of Work
2.2 Key Questions Answered in the Report

3.1 Global Clinical Biomarkers Market: Research Methodology
3.2 Data Sources
3.3 Secondary Data Sources
3.4 Market Estimation Model
3.5 Criteria for Company Profiling

4.1 Introduction
4.2 Clinical Biomarkers Approaches in Precision Medicine
4.3 Market Available Clinical Biomarkers
4.4 Global Footprint

5.1 Overview
5.2 Impact Analysis
5.3 Market Drivers
5.3.1 Increasing Prevalence of Infectious Diseases and Various Types of Cancer, Globally
5.3.2 Increase in Adoption of Personalized Medicine
5.3.3 Growing Focus on Biomarkers Research and Development Programs
5.3.4 Rising Demand for Non-Invasive Diagnosis
5.4 Market Restraints
5.4.1 Uncertain Reimbursement Policies Pertaining to Clinical Biomarkers
5.4.2 Requirement of High Capital Investment Hindering Expansion
5.4.3 Issues Related to Clinical Validity of Biomarkers-Based Tests
5.5 Market Opportunities
5.5.1 Massive Scope for Adoption of Clinical Biomarkers in Emerging Nations
5.5.2 Technological Advancements in Clinical Biomarkers-Based Tests
5.5.3 Increased Use of Clinical Biomarkers in Widespread Applications

6.1 Key Strategies and Developments
6.1.1 Synergistic Activities
6.1.2 Product Approvals
6.1.3 Product Launches and Upgradations
6.1.4 Mergers and Acquisitions
6.1.5 Funding and Expansion
6.2 Market Share Analysis
6.3 Growth Share Analysis (Opportunity Mapping)
6.3.1 By Company

7.1 Diagnostic Biomarkers
7.2 Predictive Biomarkers
7.3 Prognostic Biomarkers

8.1 Cancer Biomarkers
8.1.1 Breast Cancer Biomarkers
8.1.2 Lung Cancer Biomarkers
8.1.3 Colorectal Cancer Biomarkers
8.1.4 Prostate Cancer Biomarkers
8.2 Cardiac Biomarkers
8.3 Neurological Biomarkers
8.4 Infectious Disease
8.5 Immunological Biomarkers
8.6 Non-Invasive Prenatal Testing
8.7 Other Clinical Areas

9.1 Real-Time PCR
9.2 Enzyme-Linked Immuno Sorbent Assay (ELISA)
9.3 Immunohistochemistry (IHC)
9.4 Next-Generation Sequencing (NGS)
9.5 Other Technologies

10.1 Overview
10.2 Research and Academic Laboratories
10.3 Biopharmaceutical and Biotech Companies
10.4 Diagnostic Centers
10.5 Other End Users

11.1 Overview
11.2 North America
11.2.1 U.S.
11.2.2 Canada
11.3 Europe
11.3.1 Germany
11.3.2 U.K.
11.3.3 France
11.3.4 Italy
11.3.5 Spain
11.3.6 Rest-of-Europe
11.4 Asia-Pacific
11.4.1 China
11.4.2 Japan
11.4.3 India
11.4.4 Australia
11.4.5 Singapore
11.4.6 Rest-of-APAC
11.5 Latin America
11.5.1 Brazil
11.5.2 Mexico
11.5.3 Rest-of-Latin America
11.6 Rest-of-the-World

12.1 Overview
12.2 Abbott Laboratories
12.2.1 Company Overview
12.2.2 Role of Abbott Laboratories plc in the Global Clinical Biomarkers Market
12.2.3 Financials
12.2.4 Key Insights about Financial Health of the Company
12.2.5 SWOT Analysis
12.3 Agilent Technologies, Inc.
12.3.1 Company Overview
12.3.2 Role of Agilent Technologies, Inc. in the Global Clinical Biomarkers Market
12.3.3 Financials
12.3.4 Key Insights about Financial Health of the Company
12.3.5 SWOT Analysis
12.4 ALCEDIAG
12.4.1 Company Overview
12.4.2 Role of ALCEDIAG in Global Clinical Biomarkers Market
12.4.3 SWOT Analysis
12.5 Becton, Dickinson and Company
12.5.1 Company Overview
12.5.2 Role of Becton, Dickinson and Company in the Global Clinical Biomarkers Market
12.5.3 Financials
12.5.4 Key Insights about Financial Health of the Company
12.5.5 SWOT Analysis
12.6 bioMérieux S.A.
12.6.1 Company Overview
12.6.2 Role of bioMérieux S.A. in the Global Clinical Biomarkers Market
12.6.3 Financials
12.6.4 Key Insights about Financial Health of the Company
12.6.5 SWOT Analysis
12.7 Bio-Rad Laboratories, Inc.
12.7.1 Company Overview
12.7.2 Role of Bio-Rad Laboratories, Inc. in the Global Clinical Biomarkers Market
12.7.3 Financials
12.7.4 Key Insights about Financial Health of the Company
12.7.5 SWOT Analysis
12.8 CENTOGENE N.V.
12.8.1 Company Overview
12.8.2 Role of CENTOGENE N.V. in the Global Clinical Biomarkers Market
12.8.3 Financials
12.8.4 Key Insights about Financial Health of the Company
12.8.5 SWOT Analysis
12.9 F. Hoffmann-La Roche Ltd.
12.9.1 Company Overview
12.9.2 Role of F. Hoffmann-La Roche Ltd. in the Global Clinical Biomarkers Market
12.9.3 Financials
12.9.4 Key Insights about Financial Health of the Company
12.9.5 SWOT Analysis
12.10 Enzo Biochem Inc.
12.10.1 Company Overview
12.10.2 Role of Enzo Biochem Inc. in the Global Clinical Biomarkers Market
12.10.3 Financials
12.10.4 Key Insights about Financial Health of the Company
12.10.5 SWOT Analysis
12.11 Hologic, Inc.
12.11.1 Company Overview
12.11.2 Role of Hologic, Inc. in the Global Clinical Biomarkers Market
12.11.3 Financials
12.11.4 Key Insights about Financial Health of the Company
12.11.5 SWOT Analysis
12.12 Illumina, Inc.
12.12.1 Company Overview
12.12.2 Role of Illumina, Inc. in the Global Clinical Biomarkers Market
12.12.3 Financials
12.12.4 Key Insights about Financial Health of the Company
12.12.5 SWOT Analysis
12.13 Myriad Genetics, Inc.
12.13.1 Company Overview
12.13.2 Role of Myriad Genetics, Inc. in the Global Clinical Biomarkers Market
12.13.3 Financials
12.13.4 Key Insights about Financial Health of the Company
12.13.5 SWOT Analysis
12.14 Quest Diagnostics Incorporated
12.14.1 Company Overview
12.14.2 Role of Quest Diagnostics Incorporated in the Global Clinical Biomarkers Market
12.14.3 Financials
12.14.4 SWOT Analysis
12.15 QIAGEN N.V.
12.15.1 Company Overview
12.15.2 Role of QIAGEN N.V. plc in the Global Clinical Biomarkers Market
12.15.3 Financials
12.15.4 Key Insights about Financial Health of the Company
12.15.5 SWOT Analysis
12.16 Thermo Fisher Scientific Inc.
12.16.1 Company Overview
12.16.2 Role of Thermo Fisher Scientific in the Global Clinical Biomarkers Market
12.16.3 Financials
12.16.4 Key Insights about Financial Health of the Company
12.16.5 SWOT Analysis

Table 4.1: Key Commercialized Products Offered by Major Market Players
Table 5.1: Impact Analysis of Market Drivers
Table 5.2: Impact Analysis of Market Restraints
Table 8.1: Key Cancer Biomarkers Products Offered by Major Market Players
Table 8.2: Key Cancer Biomarkers Products Offered by Major Market Players
Table 8.3: Key Lung Cancer Biomarkers Products Offered by Major Market Players
Table 8.4: Key Colorectal Cancer Biomarkers Products Offered by Major Market Players
Table 8.5: Key Prostate Cancer Biomarkers Products Offered by Major Market Players
Table 8.6: Key Cardiac Biomarkers Products Offered by Major Market Players
Table 8.7: Key Neurological Biomarkers Products Offered by Major Market Players
Table 8.8: Key Infectious Disease Biomarkers Products Offered by Major Market Players
Table 8.9: Key Immunological Biomarkers Products Offered by Major Market Players
Table 8.10: Key Immunological Biomarkers Products Offered by Major Market Players
Table 8.11: Key Immunological Biomarkers Products Offered by Major Market Players
Table 9.1: Key RT-PCR-Based Biomarkers Products Offered by Major Market Players
Table 9.2: Key ELISA-Based Biomarkers Products Offered by Major Market Players
Table 9.3: Key IHC-Based Biomarkers Products Offered by Major Market Players
Table 9.4: Key NGS-Based Biomarkers Products Offered by Major Market Players
Table 9.5: Other Technologies-Based Biomarkers Products Offered by Major Market Players

Figure 1: Total Global Disease Burden by Cause, 2017
Figure 2: Impact Analysis of Market Drivers and Market Challenges on Global Clinical Biomarkers Market
Figure 3: Share of Key Developments and Strategies, 2016-2019
Figure 4: Dominating Segments of the Global Clinical Biomarkers Market, 2019 and 2029
Figure 5: Global Clinical Biomarkers Market (by Product), 2019 and 2029
Figure 6: Global Clinical Biomarkers Market (by Clinical Area), 2019 and 2029
Figure 7: Global Clinical Biomarkers Market (by Technology), 2019 and 2029
Figure 8: Global Clinical Biomarkers Market (by End User), 2019 and 2029
Figure 9: Global Clinical Biomarkers Market (by Region), 2019 and 2029
Figure 2.1: Global Clinical Biomarkers Market Segmentation
Figure 3.1: Global Clinical Biomarkers Market Research Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: Global Clinical Biomarkers Market, 2018 and 2029 ($Billion)
Figure 5.1: Number of Deaths by Top 18 Infectious Diseases, 2015
Figure 5.2: Number of Deaths (in Million) by Different Forms of Cancer, 2018
Figure 6.1: Share of Key Developments and Strategies, 2016–2019
Figure 6.2: Synergistic Activities Share (by Company), 2016 – 2019
Figure 6.3: Product Approval Share (by Company), 2016 –2019
Figure 6.4: Product Launches and Upgrades Share (by Company), 2016 –2019
Figure 6.5: Mergers and Acquisitions Share (by Company), 2016 –2019
Figure 6.6: Market Share Analysis for the Global Clinical Biomarkers Market, 2018
Figure 6.7: Growth Share Matrix for Global Clinical Biomarkers Market (by Company), 2018
Figure 7.1: Global Clinical Biomarkers Market (by Type), 2018-2029 ($Billion)
Figure 7.2: Global Clinical Biomarkers Market for Diagnostic Biomarkers, 2018-2029 ($Billion)
Figure 7.3: Global Clinical Biomarkers Market for Predictive Biomarkers, 2018-2029 ($Billion)
Figure 7.4: Global Clinical Biomarkers for Prognostic Biomarkers, 2018-2029 ($Billion)
Figure 8.1: Global Clinical Biomarkers Market (by Clinical Area), 2018-2029 ($Billion)
Figure 8.2: Global Clinical Biomarkers Market for Cancer Biomarkers, 2018-2029 ($Billion)
Figure 8.3: Global Clinical Biomarkers Market for Breast Cancer Biomarkers, 2018-2029 ($Billion)
Figure 8.4: Global Clinical Biomarkers Market for Lung Cancer Biomarkers, 2018-2029 ($Billion)
Figure 8.5: Global Clinical Biomarkers Market for Colorectal Cancer Biomarkers, 2018-2029 ($Billion)
Figure 8.6: Global Clinical Biomarkers Market for Prostate Cancer Biomarkers, 2018-2029 ($Billion)
Figure 8.7: Global Clinical Biomarkers Market for Cardiac Biomarkers, 2018-2029 ($Billion)
Figure 8.8: Global Clinical Biomarkers Market for Neurological Biomarkers, 2018-2029 ($Billion)
Figure 8.9: Global Clinical Biomarkers Market for Infectious Disease Biomarkers, 2018-2029 ($Billion)
Figure 8.10: Global Clinical Biomarkers Market for Immunological Biomarkers, 2018-2029 ($Billion)
Figure 8.11: Global Clinical Biomarkers Market for Non-Invasive Prenatal Testing, 2018-2029 ($Billion)
Figure 8.12: Global Clinical Biomarkers Market for Other Clinical Areas, 2018-2029 ($Billion)
Figure 9.1: Global Clinical Biomarkers Market for Real Time PCR, 2018-2029 ($Billion)
Figure 9.2: Global Clinical Biomarkers Market for ELISA, 2018-2029 ($Billion)
Figure 9.3: Global Clinical Biomarkers Market for IHC, 2018-2029 ($Billion)
Figure 9.4: Global Clinical Biomarkers Market for NGS, 2018-2029 ($Billion)
Figure 9.5: Global Clinical Biomarkers Market for Other Technologies, 2018-2029 ($Billion)
Figure 10.1: Global Clinical Biomarkers Market (by End User)
Figure 10.2: Global Clinical Biomarkers Market (by End User), 2018-2029 ($Billion)
Figure 10.3: Global Clinical Biomarkers Market for Research and Academic Laboratories, 2018-2029 ($Billion)
Figure 10.4: Global Clinical Biomarkers Market for Biopharmaceutical and Biotech Companies, 2018-2029 ($Billion)
Figure 10.5: Global Clinical Biomarkers Market for Diagnostic Centres, 2018-2029 ($Billion)
Figure 10.6: Global Clinical Biomarkers Market for Other End Users, 2018-2029 ($Billion)
Figure 11.1: Global Clinical Biomarkers Market (by Region), 2019 and 2029 ($Billion)
Figure 11.2: Global Clinical Biomarkers Market (by Region), 2018-2029 ($Billion)
Figure 11.3: Global Clinical Biomarkers Market Share (by Region), 2018 ($Billion)
Figure 11.4: Global Clinical Biomarkers Market Share (by Region), 2029 ($Billion)
Figure 11.5: North America Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.6: North America Clinical Biomarkers Market (by Country), 2018-2029 ($Billion)
Figure 11.7: North America: Market Dynamics
Figure 11.8: The U.S. Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.9: Canada Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.10: Europe Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.11: Europe: Market Dynamics
Figure 11.12: Europe Clinical Biomarkers Market (by Country), 2018-2029 ($Billion)
Figure 11.13: Germany Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.14: U.K. Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.15: France Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.16: Italy Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11 17: Spain Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.18: Rest-of-Europe Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.19: Asia-Pacific Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.20: APAC: Market Dynamics
Figure 11.21: APAC Global Clinical Biomarkers Market (by Country), 2018-2029 ($Billion)
Figure 11.22: China Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.23: Japan Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.24: India Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.25: Australia Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.26: Singapore Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.27: Rest-of-Asia Pacific Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.28: Latin America Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.29: Latin America: Market Dynamics
Figure 11.30: Latin America Clinical Biomarkers Market (by Country), 2018-2029 ($Billion)
Figure 11.31: Brazil Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.32: Mexico Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.33: Rest-of-Latin America Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 11.34: RoW Clinical Biomarkers Market, 2018-2029 ($Billion)
Figure 12.1: Total Number of Companies Profiled
Figure 12.2: Abbott Laboratories: Overall Product Portfolio
Figure 12.3: Abbott Laboratories: Overall Financials, 2016-2018
Figure 12.4: Abbott Laboratories: Revenue (by Segment), 2016-2018
Figure 12.5: Abbott Laboratories: Revenue Split for Diagnostics, 2016-2018
Figure 12.6: Abbott Laboratories: Revenue (by Region), 2016-2018
Figure 12.7: Abbott Laboratories: R&D Expenditure, 2016-2018
Figure 12.8: Abbott Laboratories: SWOT Analysis
Figure 12.9: Agilent Technologies, Inc.: Overall Product Portfolio
Figure 12.10: Agilent Technologies, Inc.: Overall Financials, 2017-2019
Figure 12.11: Agilent Technologies, Inc.: Revenue (by Segment), 2017-2019
Figure 12.12: Agilent Technologies, Inc.: Revenue (by Region), 2017-2019
Figure 12.13: Agilent Technologies, Inc.: R&D Expenditure, 2017-2019
Figure 12.14: Agilent Technologies, Inc.: SWOT Analysis
Figure 12.15: ALCEDIAG: Overall Product Portfolio
Figure 12.16: ALCEDIAG: SWOT Analysis
Figure 12.17: Becton, Dickinson and Company: Overall Product Portfolio
Figure 12.18: Becton, Dickinson and Company: Overall Financials, 2017-2019
Figure 12.19: Becton, Dickinson and Company: Revenue (by Segment), 2017-2019
Figure 12.20: Becton, Dickinson and Company: Revenue (by Sub-Segment – BD Life Sciences), 2017-2019
Figure 12.21: Becton, Dickinson and Company: Revenue (by Region), 2017-2019
Figure 12.22: Becton, Dickinson and Company: R&D Expenditure, 2017-2019
Figure 12.23: Becton, Dickinson and Company: SWOT Analysis
Figure 12.24: bioMérieux S.A.: Overall Product Portfolio
Figure 12.25: bioMérieux S.A.: Overall Financials, 2016-2018
Figure 12.26: bioMérieux S.A.: Revenue (by Segment), 2016-2018
Figure 12.27: bioMérieux S.A.: Revenue (by Region), 2016-2018
Figure 12.28: bioMérieux S.A.: R&D Expenditure, 2016-2018
Figure 12.29: bioMérieux S.A.: SWOT Analysis
Figure 12.30: Bio-Rad Laboratories, Inc: Overall Product Portfolio
Figure 12.31: Bio-Rad Laboratories, Inc.: Overall Financials, 2016-2018
Figure 12.32: Bio-Rad Laboratories, Inc.: Sales (by Segment), 2016-2018
Figure 12.33: Bio-Rad Laboratories, Inc.: Sales (by Region), 2016-2018
Figure 12.34: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2016-2018
Figure 12.35: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 12.36: CENTOGENE N.V.: Overall Product Portfolio
Figure 12.37: CENTOGENE N.V.: Overall Financials, 2016-2018
Figure 12.38: CENTOGENE N.V.: Sales (by Segment), 2016-2018
Figure 12.39: CENTOGENE N.V.: Sales (by Region), 2016-2018
Figure 12.40: CENTOGENE N.V.: R&D Expenditure, 2016-2018
Figure 12.41: CENTOGENE N.V.: SWOT Analysis
Figure 12.42: F. Hoffmann-La Roche Ltd.: Overall Product Portfolio
Figure 12.43: F. Hoffmann-La Roche Ltd.: Overall Financials, 2016-2018
Figure 12.44: F. Hoffmann-La Roche Ltd.: Sales (by Segment), 2016-2018
Figure 12.45: F. Hoffmann-La Roche Ltd.: Sales (by Region), 2016-2018
Figure 12.46: F. Hoffmann-La Roche Ltd.: R&D Expenditure, 2016-2018
Figure 12.47: F. Hoffmann-La Roche Ltd.: SWOT Analysis
Figure 12.48: Enzo Biochem Inc.: Overall Product Portfolio
Figure 12.49: Enzo Biochem Inc.: Overall Financials, 2017-2019
Figure 12.50: Enzo Biochem Inc.: Revenue (by Segment), 2017-2019
Figure 12.51: Enzo Biochem Inc.: Revenue (by Region), 2017-2019
Figure 12.52: Enzo Biochem Inc.: R&D Expenditure, 2017-2019
Figure 12.53: Enzo Biochem Inc.: SWOT Analysis
Figure 12.54: Hologic, Inc.: Overall Product Portfolio
Figure 12.55: Hologic, Inc.: Overall Financials, 2017-2019
Figure 12.56: Hologic, Inc.: Sales (by Segment), 2017-2019
Figure 12.57: Hologic, Inc.: Sales (by Region), 2017-2019
Figure 12.58: Hologic, Inc.: R&D Expenditure, 2017-2019
Figure 12.59: Hamilton, Inc.: SWOT Analysis
Figure 12.60: Illumina, Inc: Overall Product Portfolio
Figure 12.61: Illumina, Inc.: Overall Financials, 2016-2018
Figure 12.62: Illumina, Inc.: Sales (by Segment), 2016-2018
Figure 12.63: Illumina, Inc.: Sales (by Region), 2016-2018
Figure 12.64: Illumina, Inc.: R&D Expenditure, 2016-2018
Figure 12.65: Illumina, Inc.: SWOT Analysis
Figure 12.66: Myriad Genetics, Inc.: Overall Product Portfolio
Figure 12.67: Myriad Genetics, Inc.: Overall Financials, 2017-2019
Figure 12.68: Myriad Genetics, Inc.: Sales (by Segment), 2017-2019
Figure 12.69: Myriad Genetics, Inc.: R&D Expenditure, 2017-2019
Figure 12.70: Myriad Genetics, Inc.: SWOT Analysis
Figure 12.71: Quest Diagnostics Incorporated, Inc.: Overall Product Portfolio
Figure 12.72: Quest Diagnostics Incorporated: Overall Financials, 2016-2018
Figure 12.73: Quest Diagnostics Incorporated.: Sales (by Segment), 2016-2018
Figure 12.74: Quest Diagnostics Incorporated: SWOT Analysis
Figure 12.75: QIAGEN N.V.: Overall Product Portfolio
Figure 12.76: QIAGEN N.V.: Overall Financials, 2016-2018
Figure 12.77: QIAGEN N.V.: Revenue (by Segment), 2016-2018
Figure 12.78: QIAGEN N.V.: Revenue (by Region), 2016-2018
Figure 12.79: QIAGEN N.V.: R&D Expenditure, 2016-2018
Figure 12.80: QIAGEN N.V.: SWOT Analysis
Figure 12.81: Thermo Fisher Scientific Inc.: Overall Product Portfolio
Figure 12.82: Thermo Fisher Scientific Inc.: Overall Financials, 2016-2018
Figure 12.83: Thermo Fisher Scientific Inc: Sales (by Segment), 2016-2018
Figure 12.84: Thermo Fisher Scientific Inc.: Sales (by Region), 2016-2018
Figure 12.85: Thermo Fisher Scientific Inc.: R&D Expenditure, 2016-2018
Figure 12.86: Thermo Fisher Scientific Inc.: SWOT Analysis